four
serotyp
dengu
viru
respons
approxim
million
infect
annual
billion
peopl
risk
infect
make
denv
widespread
arbovir
diseas
symptomat
denv
infect
present
debilit
febril
diseas
known
dengu
fever
df
seriou
case
progress
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
fatal
patient
receiv
fluid
replac
current
approv
therapi
denv
infect
clinic
autopsi
studi
indic
cell
mononuclear
phagocyt
lineag
includ
monocytesmacrophag
dendrit
cell
primari
target
denv
vivo
addit
epidemiolog
studi
show
dhfdss
often
occur
patient
secondari
heterotyp
denv
infect
infant
matern
transfer
dengu
immun
antibodydepend
enhanc
ade
thought
major
contributor
sever
diseas
follow
secondari
infect
secondari
infect
heterolog
serotyp
viru
form
immun
complex
preexist
subneutr
antibodi
bind
fcreceptorbear
cell
lead
increas
infect
viral
replic
cell
biolog
ade
fulli
understood
propos
mechan
includ
increas
viru
attach
cell
surfac
increas
effici
postattach
step
due
fcreceptormedi
signal
deliveri
antibodyviru
complex
favor
locat
endocyt
compart
direct
alter
fusion
process
review
recent
shown
interferoninduc
transmembran
ifitm
protein
restrict
replic
multipl
virus
includ
influenza
iav
sar
coronaviru
filovirus
ebola
marburg
virus
flavivirus
includ
dengu
west
nile
virus
wherea
vesicular
stomat
viru
less
effici
restrict
group
also
demonstr
ifitm
protein
restrict
addit
ifitmmedi
restrict
flavivirus
confirm
two
subsequ
studi
ifitm
protein
rel
small
amino
acid
share
common
topolog
two
conserv
transmembran
domain
short
highli
conserv
cytoplasm
region
lumin
amino
carboxytermini
human
express
wide
rang
tissu
express
limit
bone
name
suggest
ifitm
protein
strongli
upregul
type
ii
interferon
cell
express
basal
level
one
protein
current
ifitm
protein
known
mediat
innat
immun
inhibit
viral
infect
block
viral
entri
demonstr
restrict
entri
mediat
iav
sar
coronaviru
filoviru
entri
protein
vitro
abrog
infect
three
flaviviru
viruslik
particl
vlp
suggest
ifitm
protein
also
restrict
flaviviru
infect
block
viru
entri
agreement
jiang
et
al
shown
ifitm
protein
restrict
infect
flaviviru
vlp
inhibit
replic
flaviviru
replicon
contrast
ifitm
inhibit
entri
process
amphotrop
mous
leukemia
viru
mlv
machupo
viru
macv
lassa
viru
lasv
lymphocyt
choriomening
viru
lcmv
current
clear
distinguish
entri
mechan
ifitmrestrict
ifitminsensit
virus
ifitm
protein
suppress
viral
entri
addit
ifitmmedi
restrict
bypass
induc
viral
fusion
plasma
membran
suggest
site
mechan
viral
entri
affect
sensit
ifitmmedi
restrict
given
potenti
import
ade
sever
dengu
diseas
lack
full
understand
biolog
ade
attract
hypothesi
unlik
direct
denv
infect
ademedi
denv
infect
bypass
ifitmmedi
restrict
therebi
increas
viral
replic
diseas
sever
secondari
infect
studi
sought
determin
ade
could
bypass
ifitmmedi
restrict
altern
ifitm
protein
could
contribut
control
denv
secondari
infect
well
previou
studi
ifitmmedi
restrict
flavivirus
use
cell
line
lack
fc
receptor
infect
human
myelogen
leukemia
cell
bear
denv
direct
infect
antibodyopson
denv
ademedi
infect
show
ifitm
protein
abl
restrict
direct
ademedi
infect
infect
mode
appear
equal
sensit
ifitmmedi
restrict
first
investig
basal
interferoninduc
express
ifitm
protein
cell
use
antibodi
recogn
alon
one
recogn
western
blot
analysi
show
rest
cell
express
basal
level
andor
treatment
human
h
strongli
upregul
express
fig
studi
restrict
activ
ifitm
protein
transduc
cell
stabli
express
myctag
vector
alon
select
transduc
cell
puromycin
western
blot
analysi
use
antibodi
cmyc
show
robust
express
ifitm
protein
fig
verifi
activ
infect
transduc
cell
viral
pseudoparticl
contain
mlv
genom
encod
enhanc
green
fluoresc
protein
egfp
pseudotyp
entri
protein
iav
macv
pseudoviru
infect
measur
two
day
later
flow
cytometri
expect
overexpress
potent
restrict
infect
mlvegfp
viru
pseudotyp
iav
macv
entri
protein
fig
next
infect
cell
infecti
new
guinea
c
strain
ngc
propag
mosquito
cell
incub
media
alon
enhanc
titer
monoclon
antibodi
dengu
prm
envelop
e
use
two
commerci
avail
antibodi
bind
dengu
viru
structur
protein
prm
e
respect
antiprm
antibodi
opson
virion
fulli
matur
antibodi
e
opson
virion
review
previous
describ
dengu
virion
incub
antibodi
media
alon
subsequ
incub
cell
previou
studi
shown
intracellular
stain
denv
antigen
less
h
postinfect
cell
indic
singl
round
infect
accordingli
evalu
viral
entri
assess
product
infect
intracellular
prmstain
h
postinfect
expect
direct
antibodyindepend
infect
multipl
infect
moi
express
potent
inhibit
infect
compar
vectortransduc
cell
ademedi
infect
moi
baselin
infect
increas
roughli
threefold
indic
success
ade
express
continu
potent
inhibit
infect
n
per
condit
p
similarli
moi
observ
less
effici
restrict
compar
restrict
level
direct
ademedi
infect
fig
consist
previou
studi
restrict
denv
infect
less
effici
either
quantifi
viral
load
supernat
standard
plaqu
assay
bhk
cell
overexpress
effect
restrict
ademedi
infect
suppress
viral
product
fig
n
p
final
verifi
gener
observ
confirm
murin
macrophag
stabli
express
murin
ortholog
fig
n
asterisk
indic
p
conclud
restrict
ademedi
denv
infect
cell
subsequ
investig
whether
endogen
ifitm
protein
contribut
denv
restrict
stabli
transduc
cell
express
previous
character
shrna
control
nontarget
shrna
scrambl
select
transduc
cell
puromycin
express
nearli
undetect
cell
express
shrna
target
wherea
level
unaffect
shrna
target
reduc
express
slightli
shrna
target
substanti
reduc
express
fig
previous
observ
deplet
increas
infect
iav
pseudovirus
almost
wherea
littl
increas
infect
observ
shrna
target
fig
similarli
infect
moi
knockdown
roughli
doubl
infect
rate
direct
ademedi
infect
fig
n
p
increas
less
pronounc
higher
moi
remain
statist
signific
data
show
endogen
cell
restrict
ademedi
denv
infect
fig
show
ade
bypass
ifitmmedi
restrict
leav
open
possibl
ademedi
infect
quantit
less
sensit
restrict
direct
infect
determin
ifitm
protein
restrict
ademedi
infect
extent
direct
infect
identifi
pilot
studi
viru
titer
direct
ademedi
infect
result
compar
infect
use
titer
investig
effect
ifitm
overexpress
deplet
fig
overexpress
cell
condit
nearli
ident
restrict
observ
direct
ademedi
infect
fig
similarli
deplet
cell
compar
increas
infect
observ
fig
conclud
ifitm
protein
restrict
ademedi
infect
direct
infect
similar
effici
previous
shown
ifitmmedi
restrict
depend
site
mechan
viral
entri
find
rais
key
question
ade
facilit
bypass
restrict
instead
ifitm
protein
contribut
control
secondari
infect
includ
result
dhfdss
data
show
clearli
human
myelogen
leukemia
cell
line
wide
use
studi
ade
ifitm
protein
restrict
ademedi
infect
effici
direct
infect
therefor
find
evid
support
hypothesi
ademedi
denv
infect
bypass
less
sensit
ifitmmedi
restrict
formal
possibl
differ
cell
type
antibodi
properti
viral
strain
could
alter
sensit
ademedi
infect
ifitm
restrict
howev
show
observ
consist
across
two
differ
cell
line
two
speci
express
respect
ifitm
ortholog
addit
suggest
patient
dhf
exhibit
lower
level
patient
df
review
may
lead
reduc
ifitminduct
vivo
studi
may
necessari
clarifi
possibl
nonetheless
observ
suggest
therapeut
strategi
specif
induc
ifitm
activ
could
control
primari
secondari
dengu
viru
infect
date
mechan
ifitmmedi
restrict
remain
elus
previous
demonstr
ifitm
protein
interfer
virion
access
acid
cellular
compart
furthermor
induc
viral
fusion
plasma
membran
bypass
ifitmmedi
restrict
support
mechan
oper
within
endocyt
pathway
work
studi
show
ifitm
protein
restrict
ademedi
denv
infect
effici
direct
infect
distinguish
possibl
mechan
ade
includ
alter
viral
attach
endocytosi
andor
fusion
howev
similar
sensit
direct
ademedi
infect
ifitm
restrict
indic
infect
mode
share
common
featur
render
sensit
ifitm
protein
human
embryon
kidney
cell
murin
macrophag
cell
grown
dulbecco
minim
essenti
medium
dmem
invitrogen
human
myelogen
leukemia
cell
grown
roswel
park
memori
institut
rpmi
medium
invitrogen
media
supplement
fetal
bovin
serum
uml
penicillin
streptomycin
human
obtain
nih
biodefens
emerg
infecti
research
resourc
depositori
niaid
nih
use
stimul
cell
indic
concentr
growth
media
h
plasmid
encod
cmyctag
ifitm
protein
pqcxip
vector
plasmid
encod
control
shrna
shrna
target
ifitm
pr
vector
describ
transduc
cell
select
supplement
media
puromycin
invitrogen
respect
cell
lyse
thermo
scientif
western
blot
analysi
perform
previous
describ
cmyctag
ifitm
protein
detect
murin
monoclon
anticmyc
antibodi
santa
cruz
biotechnolog
endogen
ifitm
protein
express
detect
polyclon
rabbit
santa
cruz
biotechnolog
rabbit
proteintech
group
cross
react
protein
antitubulin
antibodi
sigma
use
load
control
viral
entri
protein
plasmid
procedur
gener
pseudotyp
mlvegfp
describ
entri
protein
use
iav
ha
protein
glycoprotein
gp
machupo
viru
carvallo
similarli
transduct
cell
mlvegfp
pseudoviru
infect
procedur
describ
rel
infect
calcul
normal
infect
control
cell
new
guinea
c
strain
ngc
propag
aed
albopictu
cell
clarifi
centrifug
store
viru
titer
measur
standard
plaqu
assay
bhk
cell
direct
ademedi
infect
perform
base
publish
protocol
minor
modif
murin
antibodi
purchas
millipor
briefli
incub
rpmi
contain
fb
without
enhanc
titer
ng
moi
ng
moi
antibodi
ng
moi
total
volum
min
cell
similar
volum
media
plate
infect
similarli
pseudoviru
infect
procedur
incub
h
cell
wash
dpb
incub
h
harvest
cell
flow
cytometri
supernat
plaqu
assay
cell
assay
product
infect
intracellular
prm
stain
analyz
flow
cytometri
supernat
clarifi
centrifug
frozen
plaqu
assay
perform
bhk
cell
infect
protocol
slightli
modifi
adher
cell
cell
seed
overnight
plate
infect
similar
total
volum
l
viru
virusantibodi
complex
dmem
contain
fb
next
day
infect
wash
cell
incub
day
harvest
flow
cytometri
enhanc
titer
base
previou
studi
enhanc
titer
empir
determin
pilot
experi
use
serial
dilut
antibodi
complex
moi
moi
dilut
gave
best
enhanc
infect
cell
subsequ
use
experi
statist
analysi
perform
use
onetail
student
test
p
consid
statist
signific
